受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 此前许峰律师已收到收到北京金融法院判决书，投资者获得胜诉，此后律师代理投资者向法院申请强制 执行，目前投资者已经通过强制执行获赔到位。律师团队还在继续推进后续案件的立案工作，还在继续 接受其他投资者的索赔委托，但该案的诉讼时效目前仅剩下二十天左右，"过期作废"。 此前弘高创意公告收到证监会处罚结论，经查明，弘高创意违法事实如下： 弘高股份下属子公司北京弘高建筑装饰设计工程有限公司通过虚构工程项目合同、未对工程项目如实核 算、未对已结算项目及时做结算会计处理等方式虚增收入和利润。 相关事项导致弘高股份2015年、2016年、2017年、2018年、2019年、2020年、2021年、2022年年度报告 存在虚假记载。 2015年虚增收入10，389.97万元，占当期披露营业收入的3.16%，虚增利润2，628.53万元，占当期披露 利润总额的7.18%。 2016年虚增收入21，683.13万元，占 ...

Group 1 - Chuling Information (300250) experienced a consecutive 20% limit-up for two trading days, with a total increase of 44% [1][3] - On September 23, Chuling Information disclosed its shareholding in Moer Thread, revealing an indirect holding of approximately 0.0229% through the Zhongyi Fund, which holds about 2.12% of Moer Thread [2][3] - The investment in the Zhongyi Fund amounts to 100 million RMB, focusing on the digital economy and modern mobile information industry chain, which is expected to synergize with the company's core business [2][3] Group 2 - Chuling Information emphasized that its stake in Moer Thread is minimal and urged investors to be rational and aware of investment risks [3] - Moer Thread is one of the few companies in China with full GPU development capabilities, and its Sci-Tech Innovation Board listing application is set for review on September 26 [3] - Other companies, including Ruifeng New Materials and Huachen Equipment, have also disclosed their investments in Moer Thread, indicating a broader interest in the sector [3]

目錄 2 公司資料 4 董事長致辭 6 財務摘要 7 管理層討論與分析 45 董事、監事及高級管理層 53 董事會報告 84 企業管治報告 118 獨立核數師報告 123 綜合損益及其他全面收益表 125 綜合財務狀況表 127 綜合權益變動表 128 綜合現金流量表 131 綜合財務報表附註 245 釋 義 公司資料 | 中 文 | 名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | --- | | 英文名稱： | | Venus Medtech （Hangzhou） Inc. | | 法定代表： | | 林浩昇先生1 | | 董事長： | | 胡定旭先生2 | | 註冊資本： | | 人 民 幣441,011,443元3 | | 中國總部： | | | | 註冊及辦事處地址 | | 中國杭州濱江區江陵路88號2幢3樓311室 | | 公司網址 | | http://www.venusmedtech.com/ | | 電 郵 | | inquiry@venusmedtech.com | | 香港主要營業地點： | | 香港灣仔皇后大道東248號大新金融中心40樓 | | 董事會： | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二三年十二月三十一日止年度之 年度業績公 告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 三 年 十 二 月 三 十 一 日 止 年 度（「報告期」）之未經審核 綜合業績，連同二零二二年同期 之 比較數字。 財務概要 | | 截至二零二三年 | 截至二零二二年 | | | --- | --- | --- | --- | | | 十二月三十一日 | 十二月三十一日 | | | | 止年度 | 止年度 | 同比變動 | | | ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 255.61 million, representing a 21.7% increase compared to RMB 209.97 million for the same period in 2022[9]. - Gross profit for the same period was RMB 201.25 million, up 22.6% from RMB 164.18 million year-on-year[9]. - The pre-tax loss increased by 50.3% to RMB 370.34 million from RMB 246.41 million in the previous year[9]. - The net loss for the period was RMB 366.22 million, a 52.8% increase compared to RMB 239.67 million in the prior year[9]. - The basic and diluted loss per share increased by 73.9% to RMB (0.80) from RMB (0.46) in the previous year[9]. - Other income and gains decreased by 47.0% to RMB 33.1 million, mainly due to reduced foreign exchange gains[61]. - The company reported a net cash outflow from operating activities of RMB 331,316,000 for the first half of 2023, compared to RMB 264,187,000 in the same period of 2022, indicating a worsening cash flow situation[200]. - The total equity attributable to the owners of the parent company decreased to RMB 3,312,520,000 from RMB 3,607,864,000, a decline of around 8.2%[195]. Product Development and Innovation - The company launched its first self-developed product, Venus P-Valve, in Europe, which is now available in 30 countries including Germany, Italy, and Spain[12]. - Venus P-Valve received FDA approval for an IDE application in July 2023, allowing for critical clinical research in the U.S.[12]. - The company has established a product pipeline consisting of 12 innovative devices targeting heart valve diseases, hypertrophic cardiomyopathy, and hypertension[14]. - Ongoing clinical trials include the next-generation TAVR product Venus-Vitae and the innovative Cardiovalve device[12]. - The company aims to develop new materials, bionics, imaging fusion technology, and digital sensing to enhance its product offerings[11]. - The Venus-Vitae product features a unique adaptive active anti-leak skirt design, aimed at improving patient outcomes and procedural efficiency[27]. - The company is focusing on expanding its product offerings in the mitral and tricuspid valve intervention space, which is expected to be a new growth point[45]. Sales and Market Expansion - The sales revenue of the VenusA series products reached RMB 229.8 million for the six months ended June 30, 2023, an increase of 16.9% compared to RMB 196.6 million for the same period in 2022[19]. - VenusP-Valve's sales revenue for the six months ended June 30, 2023, was RMB 25.2 million, a significant increase of RMB 16.1 million from RMB 9.1 million for the same period in 2022[25]. - VenusP-Valve has been approved in over 30 countries and regions, including the UK, Italy, and Germany, and has seen strong sales growth due to an efficient overseas sales team[21]. - The company has established a sales team of nearly 260 people covering over 420 tertiary hospitals in China, enhancing its market presence and sales capabilities[53]. - The company has expanded its international marketing strategy, covering 30 countries and regions, and appointed a new head for international congenital heart disease business to strengthen its overseas commercialization efforts[54]. Research and Development - Research and development expenses for the six months ended June 30, 2023, were RMB 294.7 million, an increase from RMB 220.3 million for the same period in 2022, representing a growth of approximately 33.6%[47]. - Research and development costs increased to RMB 294,715,000, a rise of 33.6% from RMB 220,316,000 in the previous year[187]. - The company emphasizes continuous innovation and increased R&D investment to address clinical pain points in the structural heart disease market[45]. Corporate Governance and Compliance - The interim financial report for 2023 has not been audited, but the audit committee has reviewed and found the financial performance for the six months ending June 30, 2023, to comply with relevant accounting standards[139]. - The company has implemented remedial measures to ensure compliance with listing rules, including hiring an internal control consultant to review financial reporting procedures[142]. - The internal control review found that loans to directors were not approved according to internal management systems and relevant listing rules, lacking proper credit risk assessments and documentation[149]. - The company has engaged a compliance consultant to provide training on listing rules responsibilities to directors and senior management[166]. - The audit committee believes that the procedures taken for the interim results of 2023 are appropriate and reasonable, without the need for external auditor review[170]. Financial Position and Assets - As of June 30, 2023, cash and cash equivalents were RMB 1,453.2 million, a decrease of 22.7% from RMB 1,879.4 million at the end of 2022, primarily due to increased R&D and operating expenses[76]. - The net current assets of the group as of June 30, 2023, were RMB 1,473.0 million, representing a decrease of 25.5% from RMB 1,976.9 million as of December 31, 2022[79]. - The total assets less current liabilities decreased to RMB 4,366,306,000 from RMB 4,790,731,000, indicating a reduction of about 8.8%[193]. - The company reported a foreign exchange loss of RMB 1,677,000 in the first half of 2023, compared to a significant loss of RMB 46,820,000 in the same period of 2022, indicating an improvement in foreign exchange management[200]. Share Capital and Ownership - As of June 30, 2023, the total issued share capital of the company is 441,011,443 shares, comprising 441,010,235 H shares and 1,208 non-listed foreign shares[101]. - Mr. Zeng holds 33,651,618 H shares, representing approximately 7.63% of the total issued share capital[99]. - The company has a total of 1,006 employees as of June 30, 2023, with 862 based in China and 144 overseas[88]. - The company has a stock option plan approved on July 12, 2023, with a limit of 44,101,023 H-shares, representing about 10% of all issued H-shares[123].

Financial Performance - Revenue for the six months ended June 30, 2023, was HK$485,518,000, a decrease of 4.3% from HK$507,552,000 in the same period of 2022[8]. - Gross profit for the same period was HK$417,650,000, down from HK$425,221,000, reflecting a slight decline of 1.3%[8]. - Profit for the period attributable to owners of the Company increased significantly to HK$24,194,000, compared to HK$7,208,000 in 2022, representing a growth of 235.5%[11]. - Basic and diluted earnings per share for the period were both HK$0.12, up from HK$0.04 in the previous year[8]. - Total comprehensive income for the period attributable to owners of the Company was HK$19,730,000, compared to a loss of HK$6,391,000 in the same period last year[11]. - For the six months ended June 30, 2023, the total revenue was HK$485,518,000, a decrease of 4.3% from HK$507,552,000 in the same period of 2022[62]. - Profit for the period was approximately HK$24.2 million, significantly up from approximately HK$7.2 million in the prior year, attributed to reduced product costs and lower management expenses[116]. Assets and Liabilities - Non-current assets as of June 30, 2023, amounted to HK$875,964,000, a decrease from HK$2,197,629,000 as of December 31, 2022[14]. - Current assets increased to HK$1,570,667,000 from HK$257,461,000, indicating a significant improvement in liquidity[14]. - Net assets as of June 30, 2023, were HK$1,503,815,000, up from HK$1,481,711,000 at the end of 2022[16]. - Reportable segment assets as of June 30, 2023, totaled HK$1,084,665,000, a decrease from HK$1,144,588,000 as of December 31, 2022[59]. - Reportable segment liabilities as of June 30, 2023, were HK$698,169,000, down from HK$728,486,000 at the end of 2022[59]. Cash Flow - For the six months ended June 30, 2023, net cash generated from operating activities was HK$27,453,000, compared to a net cash used of HK$7,567,000 in the same period of 2022[19]. - Net cash generated from investing activities was HK$2,124,000, an improvement from a net cash used of HK$6,771,000 in the prior year[19]. - Net cash used in financing activities increased to HK$29,533,000 from HK$27,084,000 year-over-year[19]. - Cash and cash equivalents at June 30, 2023, amounted to HK$62,888,000, up from HK$48,681,000 at the same date in 2022[19]. - The company reported a net increase in cash and cash equivalents of HK$44,000 for the period, a significant recovery from a decrease of HK$41,422,000 in the previous year[19]. Revenue Segmentation - Revenue from enterprise cloud services was HK$417,184,000, down 11.5% from HK$471,816,000 in 2022[62]. - Revenue from digital business and information technology services increased significantly to HK$68,334,000, up 91.2% from HK$35,736,000 in 2022[62]. - The enterprise cloud services segment generated revenue of approximately HK$417.2 million, down from approximately HK$471.8 million in the previous year, with a loss before income tax of approximately HK$14.9 million, improved from a loss of approximately HK$17.2 million[123]. - The digital business and information technology services segment recorded revenue of approximately HK$68.3 million for the first half of 2023, compared to approximately HK$35.7 million for the same period in 2022[137]. Employee and Compensation - The Group employed approximately 5,027 employees as of June 30, 2023, an increase from 4,351 employees a year earlier[154]. - Total salaries and allowances for employees for the six months ended June 30, 2023, were approximately HK$316.3 million, compared to HK$363.6 million for the same period in 2022[154]. - Basic salaries, other allowances, and benefits in kind totaled HK$296,000 for the first half of 2023, down from HK$313,000 in 2022, representing a decrease of 5.43%[97]. - The pension costs for defined contribution plans were HK$86,000 for the six months ended June 30, 2023, compared to HK$82,000 in the same period of 2022, marking a 4.88% increase[97]. - The company emphasizes training for employees in various skills and qualities to enhance their work performance[156]. - The company is focused on maintaining a competitive compensation structure based on employee qualifications and performance[156]. Corporate Governance and Compliance - The Company has complied with the Corporate Governance Code throughout the six months ended 30 June 2023, except for the postponement of annual general meetings due to delays in publishing audited annual results[184]. - The Company currently lacks insurance cover for legal actions against its Directors, and the Board is considering obtaining suitable insurance[185]. - The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2023, consistent with the previous year[183]. Shareholder Information - As of June 30, 2023, Mr. Yu holds a long position of 12,838,585,316 shares, representing approximately 59.11% of the company's issued shares[160]. - Mr. Chen Ming Fei holds a long position of 199,100,000 shares, representing approximately 0.91% of the company's issued shares[160]. - The directors' interests in shares of associated corporation Nan Hai include Mr. Yu's long position of 40,673,177,261 shares, representing approximately 59.25%[163]. - The Company has not granted any share options under its share option scheme since its adoption in 2012, and the scheme lapsed on May 28, 2022[166]. - The Restricted Share Award Scheme allows for a maximum of 2,462 million restricted shares to be granted to selected participants, which may include new shares issued by the Company or existing shares purchased on the market[168].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二三年六月三十日止六個月之 中期業績公告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 之未經審核綜合中期業績，連同二零二二年同期之比較數字。 財務概要 截 至截 至 二零二三年二零二二年 六月三十日六月三十日 | --- | --- | --- | |--------------|--------------|----------| | 止六個月 | 止六個月 | 同比變動 | ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （股份代號：250） （於香港註冊成立之有限公司） 中國數碼信息有限公司 截 至2023年6月30日 止 六 個 月 之 未 經 審 核 中 期 業 績 公 告 中 期 業 績 中 國 數 碼 信 息 有 限 公 司（「本 公 司」）董 事 會（「董 事 會」）謹 此 宣 佈 本 公 司 及 其 附 屬 公 司（「本 集 團」）截 至2023年6月30日 止 六 個 月 之 未 經 審 核 綜 合 業 績， 連 同2022年 之 比 較 數 字 如 下： – 1 – 簡 明 綜 合 收 益 表 截 至2023年6月30日 止 六 個 月 | --- | --- | --- | |-------|-------------- ...

目錄 | 2 | 公司資料 | | --- | --- | | 3 | 董事長致辭 | | 5 | 財務摘要 | | 6 | 管理層討論與分析 | | 44 | 董 事、監 事 及 高 級 管 理 層 | | 53 | 董事會報告 | | 81 | 企業管治報告 | | 108 | 環 境、社 會 及 管 治 報 告 | | 154 | 獨立核數師報告 | | 161 | 綜合損益及其他全面收益表 | | 163 | 綜合財務狀況表 | | 165 | 綜合權益變動表 | | 166 | 綜合現金流量表 | | 169 | 財務報表附註 | | 300 | 釋 義 | 公司資料 | 中文名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | | 英文名稱： | Venus Medtech（Hangzhou）Inc. | | 法定代表： | 曾敏先生 | | 董事長： | 曾敏先生 | | 註冊資本： | 人民幣441,011,443元1 | | 中國總部： | | | 註冊及辦事處地址 | 中國杭州濱江區江陵路88號2幢3樓311室 | | 公司網址 | http://www.venusme ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二二年十二月三十一日止年度之 年度業績公告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度（「報告期」）之 經 審 核 綜 合 業 績，連 同 二 零 二 一 年 同 期 之 經 審 核 比 較 數 字。 財務概要 截至二零二二年截至二零二一年 十二月三十一日十二月三十一日 止年度止年度 同比變動 人民幣千元 人民幣千元 | --- | --- | --- | --- | |-- ...